Home > Insider Trading > Filing (0001177648-19-000013)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1177648	Enanta Pharmaceuticals Inc	ENTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1607643	S. Nathaniel Gardiner	C/O Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown MA 02472	Sr. Vp & General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-02-12	4,000	$0.00	21,827	No	4	A	Direct
Common Stock	Acquisiton	2019-02-12	10,000	$0.00	31,827	No	4	A	Direct
Common Stock	Disposition	2019-02-12	4,579	$88.88	27,248	No	4	F	Direct
Common Stock	Disposition	2019-02-13	3,270	$95.28	23,978	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	F	Direct
No	4	S	Direct

Footnotes

Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on January 4, 2017 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2019.
Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on January 4, 2017 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2019.
Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2018.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.76, inclusive.